|
||
| |||||||
|
In recent years, accumulating evidence has demonstrated the utility of aromatase inhibitors as therapy for postmenopausal women with estrogen receptor (ER) positive advanced breast cancer. Aromatase inhibitors have already proved themselves superior, in major clinical trials, to existing hormonal therapies in the fight against breast cancer. These breakthrough findings are likely reinvigorate the market and spur growth rates. Three aromatase inhibitors are currently available in the United States; the nonsteroidal inhibitors anastrozole and letrozole and the steroidal inhibitor exemestane. Another two are available on world markets, formestane and fadozole. Several products are also available in different stages of clinical trials and are expected to enter the market soon. By the end of 2002 the world market for aromatase inhibitors was valued at $420 million, a growth of 27% over 2001. The market has been growing at a 24% average annual growth rate over the previous 5 years. Aromatase Inhibitors in Breast Cancer is a timely strategic consulting report from ASInsigts designed to bring the latest happenings in both clinical development and marketing arena to the attention of oncology product managers in the harmaceutical and medical biotech industries. The report examines the current state-of-the-science, assesses the market environment, profiles leading participants and their products and gives a helicopter view of the competitive landscape. Report Code: 0305AS1 Date Published: May 2003 Number of Pages: 25 Publisher: AS Insights Opportunity and Valuation Reports To order go to this URL: http://www.bioportfolio.com/cgi-bin/acatalog/Bioportfolio_AS_Insights_Opportunity_and_Valuation_Reports__10.html#a514
|
|
| ||||||||